(Q42873323)

English

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

scientific article published on November 1, 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116 (English)

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

object named as

Xiaochun Li

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

author name string

Wael Harb

2

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Daniel Bradford

3

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Jose Bufill

4

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Sreenivasa Nattam

5

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Jyoti Patel

6

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

William Fisher

7

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Jingwei Wu

10

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Nasser Hanna

11

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Erin M. Casey

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20881647

23 July 2024

Jane E. Latz

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20881647

23 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20881647

23 July 2024

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

full work available at URL

http://www.jto.org/article/S1556086415318414/pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20881647

23 July 2024

https://api.elsevier.com/content/article/PII:S1556086415318414?httpAccept=text/xml

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

https://api.elsevier.com/content/article/PII:S1556086415318414?httpAccept=text/plain

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

1815-1820

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Cancer statistics, 2009

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

3

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life

4

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

5

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

8

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Angiogenesis and lung cancer: prognostic and therapeutic implications

9

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

10

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

11

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

12

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

13

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

14

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

15

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

17

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

18

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

19

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer

22

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

24

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

27

1 reference

10.1097/JTO.0B013E3181EE820C

https://api.crossref.org/works/10.1097/JTO.0B013E3181EE820C

23 July 2024

Identifiers

10.1097/JTO.0B013E3181EE820C

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42873323&oldid=2216975578"